Does intestinal ultrasound combined with visceral adipose tissue more accurately predict primary non-response to infliximab in patients with Crohn's disease? A prospective, observational study.

ABSTRACT:

Background

Infliximab (IFX) is widely used for the treatment of Crohn's disease (CD), yet up to 40% patients experience primary non-response (PNR). Visceral adipose tissue (VAT) and intestinal ultrasound (IUS) could be used as noninvasive tools to predict treatment efficacy with limited value, respectively.

Objectives

This study aims to investigate the value of IUS combined with VAT in predicting PNR in CD patients.

Design

This was a single-center, prospective, and observational study.

Methods

Consecutive patients with active CD initiating regular IFX therapy were prospectively included. Patients underwent IUS at baseline (T0), week 2-4 (T1), and week 14 (T2), and CT at T0 to collected visceral fat area (VFA). Multivariable analyses and logistic regression anal

SUBMITTER: Ye M 

PROVIDER: S-EPMC12847685 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature